Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious tumors
| Inventor | Institute |
|---|---|
| Anne-Marie Mes-Masson and Diane Provencher | Centre Hospitalier de Luniversité de Montréal |
| SKU: | 161779 |
|---|---|
| Product description: | Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious tumors of patient who was chemotherapy naive at time of sampling. Results show that the intronic TP53 mutation seems to also affect transcription since neither mRNA nor protein were detected in this cel lline |
| Alternate name: | TOV-2978G |
| Gender: | Female |
| CRISPR: | No |
| Production details: | Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly. |
| Additional notes: | Patient 2978 was age 63 at diagnosis with BRCA hereditary status as negative. Patient was chemotherapy naive at sample collection. First line treatment involved surgery, Carboplatin, and taxol. There was no previous personal history of cancer nor prior oncologic treatment. The year of sampling was 2006. |
| Receptors of note: | No |
| Cat. #: | 161779 |
|---|---|
| Cancer types: | Ovarian cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Derived from high-grade serous tumors |
| Gender: | Female |
| Morphology: | Small epithelial type cells. Formed individual small aggregates |
| Growth properties: | Adherent |
| Primary citation: | Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941 |
| Shipping conditions: | Dry Ice |
|---|---|
| Growth medium: | OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin |
| Atmosphere: | Low oxygen conditions of 7% O2 and 5% CO2 |
| References: |
Vias et al. 2023. Elife. 11 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30 15(9):2566. PMID: 37174032 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.